When India joined they had to amend their patent law to allow patents for medications and as a result, they passed the Patents Act of 2005, which gave regulations and restrictions for patents being approved for pharmaceuticals. This new law was that any medication that was created as a new form from an existing drug could not be patented unless the company could provide proof that the new medication was more effective than the existing medication. Novartis created Glivec as a new medication, but it had imatinib in it which was a drug that had been previously used. Novartis AG, a Swiss pharmaceutical company was seeking a patent in India for an anti-leukemia medication that was advertised in North America as Gleevec and in the rest of the world as Glivec. India ruled that Novartis did not meet the requirements for Glivec. Novartis did not meet the requirements because they were not able to prove effectiveness of the new medication they were trying to have patented. Instead, they were only able to show that the medication Glivec had 30% higher bioavailability. Bioavailability is the portion
When India joined they had to amend their patent law to allow patents for medications and as a result, they passed the Patents Act of 2005, which gave regulations and restrictions for patents being approved for pharmaceuticals. This new law was that any medication that was created as a new form from an existing drug could not be patented unless the company could provide proof that the new medication was more effective than the existing medication. Novartis created Glivec as a new medication, but it had imatinib in it which was a drug that had been previously used. Novartis AG, a Swiss pharmaceutical company was seeking a patent in India for an anti-leukemia medication that was advertised in North America as Gleevec and in the rest of the world as Glivec. India ruled that Novartis did not meet the requirements for Glivec. Novartis did not meet the requirements because they were not able to prove effectiveness of the new medication they were trying to have patented. Instead, they were only able to show that the medication Glivec had 30% higher bioavailability. Bioavailability is the portion